The molecular quality control market size was valued at USD 230 million in 2025 and is projected to grow from USD 245 million in 2026 to USD 410 million by 2034 at a CAGR of 7% during the forecast period 2026-2034. North America dominated the molecular quality control market with a market share of 39.5% in 2025.
The molecular quality control market is evolving with the growing adoption of advanced diagnostics like PCR and NGS, driving demand for assay-specific, multi-analyte, and instrument-compatible control materials to ensure accuracy and regulatory compliance. The market is further fueled by the integration of multiplex and syndromic testing panels and the rise of decentralized, near-patient testing, which increases the need for versatile, stable, and user-friendly controls. However, growth is restrained by the premium pricing of advanced controls and the limited availability of standardized reference materials for rare or emerging targets. Opportunities lie in the expansion of personalized medicine and companion diagnostics, which require disease-specific, patient-matched controls, as well as the adoption of digital and cloud-connected laboratory systems, enabling real-time performance monitoring, automated quality management, and integration of data-driven workflows.
Download a Free Sample To learn more about this report,
Growing Adoption of Multi-Analyte Quality Control Solutions
The molecular quality control market trends are being driven by the increasing use of molecular diagnostics, stricter laboratory quality standards, and the growing demand for accurate diagnostic testing. Clinical laboratories are adopting advanced molecular quality control materials to ensure the reliability of polymerase chain reaction (PCR), next-generation sequencing (NGS), and other molecular diagnostic assays used for detecting infectious diseases, genetic disorders, and cancer. Multi-analyte and third-party quality control products are gaining popularity because they enable laboratories to verify the performance of multiple tests using a single control sample, improving efficiency and reducing operational costs. In addition, laboratory automation, digital quality management systems, and standardized testing protocols are helping laboratories maintain regulatory compliance while minimizing testing errors and improving overall diagnostic accuracy.
These developments indicate that multi-analyte quality control, laboratory automation, standardized molecular testing, and digital quality management systems will remain the key Molecular Quality Control market trends, improving diagnostic accuracy, supporting regulatory compliance, and driving long-term growth across clinical laboratories worldwide.
Growing Adoption of Molecular Diagnostics and Quality Assurance Programs
The molecular quality control market is expanding due to the increasing adoption of molecular diagnostics and the growing emphasis on quality assurance in clinical laboratories. Rising demand for accurate diagnostic testing for infectious diseases, cancer, and genetic disorders is encouraging laboratories to implement robust quality control solutions to ensure reliable test results. Advancements in PCR, next-generation sequencing, and multiplex molecular assays are further driving the need for standardized quality control materials. These factors are significantly contributing to molecular quality control market growth as healthcare providers focus on improving diagnostic accuracy and regulatory compliance.
High Cost of Quality Control Solutions and Regulatory Complexity
The molecular quality control market faces challenges due to the high cost of quality control materials, stringent regulatory requirements, and the complexity of validating molecular diagnostic assays. Clinical laboratories must invest in certified quality control products and continuous proficiency testing to comply with international accreditation standards, increasing operational expenses. Smaller laboratories often face budget constraints that limit the adoption of comprehensive quality assurance programs. Recent molecular quality control market analysis indicates that these factors continue to affect the widespread implementation of advanced molecular quality control solutions.
Expansion of Next-Generation Sequencing and Precision Medicine
The molecular quality control market is expected to benefit from the growing adoption of next-generation sequencing, precision medicine, and companion diagnostics. Increasing use of genomic testing in oncology, rare disease diagnosis, and infectious disease surveillance is creating strong demand for high-quality molecular control materials. Continuous investments in laboratory automation and digital quality management systems are also improving testing efficiency and standardization. These developments are expected to strengthen the molecular quality control market size by supporting the expansion of advanced molecular diagnostic applications worldwide.
Standardization of Testing Procedures and Data Management
The molecular quality control market continues to face challenges related to standardizing molecular testing procedures, managing complex laboratory data, and ensuring compliance with evolving regulatory standards. Variations in testing protocols, laboratory workflows, and assay performance can affect the consistency of diagnostic results across healthcare facilities. In addition, integrating digital quality management systems with laboratory information systems requires continuous investment in technology and workforce training. According to recent molecular quality control market reports, companies are focusing on automated quality management solutions and standardized molecular controls to improve laboratory performance and regulatory compliance.
Request Customizationto receive a tailored report.
Independent Controls Segment Dominated the Market with 68% Share in 2025
The independent controls segment dominated the global molecular quality controls market with a 68% share in 2025, representing a market value of USD 0.16 billion. The segment is projected to grow at a CAGR of 7.8% during 2026–2034. Its dominance is driven by their broad compatibility across multiple diagnostic platforms, ability to provide unbiased quality assessment, and increasing adoption in clinical laboratories for validating test accuracy and reliability. The growing emphasis on standardized quality assurance practices continues to strengthen the segment's market position.
The instrument-specific controls segment continues to witness steady demand owing to their optimized performance with specific diagnostic systems and their ability to improve testing accuracy. Increasing adoption of automated molecular diagnostic platforms and manufacturer-recommended quality control protocols continues to support the segment's growth.
Multi-analyte Controls Segment is Projected to Register the Fastest Growth at a CAGR of 8%
The multi-analyte controls segment is projected to register the fastest growth at a CAGR of 8% during 2026–2034. In 2025, the segment accounted for 46% of the global molecular quality controls market, with a value of USD 0.11 billion. Growth is driven by the increasing demand for comprehensive quality control solutions that validate multiple biomarkers within a single assay, improve laboratory efficiency, and reduce testing costs. Rising adoption of multiplex molecular diagnostics is expected to further support the segment's growth.
The single-analyte controls segment dominated the market owing to their widespread use in validating individual diagnostic targets and ensuring high testing accuracy for specific molecular assays. Their continued application in routine clinical diagnostics and regulatory quality assurance programs supports stable market demand.
Oncology Testing Segment is Projected to Register the Fastest Growth at a CAGR of 8.2%
The oncology testing segment is projected to register the fastest growth at a CAGR of 8.2% during 2026–2034. In 2025, the segment accounted for 25% of the global molecular quality controls market, with a value of USD 0.06 billion. Growth is driven by increasing adoption of precision oncology, expanding use of molecular biomarkers, and rising demand for highly accurate cancer diagnostic testing. Continuous advancements in companion diagnostics and personalized medicine are expected to further accelerate the segment's growth.
The infectious disease diagnostics segment dominated the market owing to the high volume of molecular testing performed for viral, bacterial, and other infectious diseases. Increasing emphasis on accurate diagnostic results and stringent laboratory quality standards continues to support the widespread adoption of molecular quality controls in infectious disease testing. The genetic testing segment continues to witness steady growth due to the expanding use of genomic testing for inherited disorders, prenatal screening, and personalized healthcare applications.
IVD Manufacturers & Contract Research Organizations Segment is Projected to Register the Fastest Growth at a CAGR of 7.9%
The IVD manufacturers & contract research organizations segment is projected to register the fastest growth at a CAGR of 7.9% during 2026–2034. In 2025, the segment accounted for 19% of the global molecular quality controls market, with a value of USD 0.04 billion. Growth is driven by increasing investments in diagnostic assay development, expanding clinical validation activities, and rising demand for standardized quality control materials during product development and regulatory approval processes. Growing innovation in molecular diagnostics continues to support the segment's expansion.
The diagnostic laboratories segment dominated the market owing to the high volume of molecular diagnostic testing, stringent quality assurance requirements, and increasing adoption of standardized laboratory practices. The hospitals segment continues to maintain steady demand as molecular testing becomes increasingly integrated into routine clinical care and disease management. The academic & research institutes segment remains an important contributor to the market through ongoing research activities, assay development, and advancements in molecular diagnostic technologies.
Speak to an Analystto discuss market opportunities.
North America molecular quality control market accounted for 39.5% of the global market, reaching USD 0.09 billion in 2025, and is projected to grow at a CAGR of 7.1% during the forecast period. The market is driven by increasing adoption of molecular diagnostics, rising demand for accurate laboratory testing, expanding use of quality control products in clinical laboratories, and stringent regulatory requirements. Continuous advancements in molecular testing technologies and growing investments in healthcare infrastructure continue to support regional market growth.
The US market was valued at USD 0.08 billion in 2025, making it the largest contributor in North America. Rising demand for high-quality molecular diagnostic testing, increasing adoption of automated laboratory workflows, expanding use of precision medicine, and continuous investments in laboratory quality assurance continue to drive market growth.
Canada's market reached USD 0.01 billion in 2025. Growing healthcare investments, increasing implementation of molecular diagnostic platforms, expanding laboratory accreditation programs, and rising demand for standardized quality control solutions continue to support steady market expansion.
Europe molecular quality control market accounted for 28% of the global market, reaching USD 0.06 billion in 2025, and is projected to grow at a CAGR of 7% during the forecast period. Rising demand for accurate diagnostic testing, increasing adoption of molecular assays, expanding laboratory automation, and stringent quality standards continue to strengthen regional market growth. Ongoing investments in advanced diagnostic technologies further support market expansion.
The UK market was valued at USD 0.01 billion in 2025. Increasing adoption of molecular diagnostics, expanding laboratory modernization initiatives, growing emphasis on quality assurance, and rising investments in precision diagnostics continue to support market growth.
Germany market accounted for USD 0.02 billion in 2025. Strong clinical laboratory infrastructure, increasing use of molecular testing technologies, expanding quality management systems, and continuous investments in diagnostic innovation continue to drive market expansion.
Asia Pacific molecular quality control market accounted for 22.5% of the global market, reaching USD 0.05 billion in 2025, and is projected to grow at a CAGR of 8.9% during the forecast period. Rising healthcare expenditure, expanding molecular diagnostic laboratories, increasing awareness of quality assurance, and growing demand for reliable diagnostic testing continue to accelerate regional market growth. Government support for laboratory modernization further strengthens market expansion.
Japan's market generated USD 0.01 billion in 2025. Increasing adoption of precision diagnostics, expanding laboratory automation, growing investments in healthcare innovation, and rising demand for standardized quality control solutions continue to support market growth.
China's market accounted for USD 0.02 billion in 2025, representing the largest share within Asia Pacific. Expanding molecular diagnostic capabilities, increasing healthcare investments, growing laboratory infrastructure, and rising adoption of advanced quality control products continue to drive market expansion.
Latin America molecular quality control market accounted for 6% of the global market, reaching USD 0.01 billion in 2025, and is projected to grow at a CAGR of 6.8% during the forecast period. Increasing healthcare investments, expanding molecular testing services, growing awareness of laboratory quality standards, and rising demand for reliable diagnostic solutions continue to support regional market growth.
Brazil market accounted for USD 0.01 billion in 2025. Rising adoption of molecular diagnostic technologies, expanding laboratory services, increasing healthcare modernization initiatives, and growing focus on quality assurance continue to support market expansion.
Middle East & Africa molecular quality control market accounted for 4% of the global market, totaling USD 0.01 billion in 2025, and is projected to grow at a CAGR of 6.4% during the forecast period. Increasing investments in healthcare infrastructure, expanding access to molecular diagnostics, growing laboratory quality improvement initiatives, and rising adoption of standardized testing protocols continue to support regional market growth.
The UAE market was valued at USD 0.003 billion in 2025. Increasing investments in advanced laboratory facilities, expanding molecular diagnostic services, growing healthcare digitization, and rising demand for quality assurance solutions continue to drive market growth.
Africa's market reached USD 0.007 billion in 2025. Improving laboratory infrastructure, increasing access to molecular diagnostic testing, expanding healthcare investments, and growing adoption of quality management systems continue to create long-term growth opportunities across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com